Michael Gollob

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7296673/publications.pdf

Version: 2024-02-01

156	10,887	53939	36203
papers	citations	47 h-index	101 g-index

160	160	160	11206
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. European Heart Journal, 2022, 43, 1500-1510.	1.0	57
2	Importance of genetic testing in unexplained cardiac arrest. European Heart Journal, 2022, 43, 3071-3081.	1.0	36
3	Atrial myopathy: A primary substrate for atrial fibrillation. Heart Rhythm, 2022, 19, 476-477.	0.3	0
4	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace, 2022, 24, 1307-1367.	0.7	108
5	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm, 2022, 19, e1-e60.	0.3	78
6	European Heart Rhythm Association (<scp>EHRA</scp>)/Heart Rhythm Society (<scp>HRS</scp>)/Asia Pacific Heart Rhythm Society (<scp>APHRS</scp>)/Latin American Heart Rhythm Society (<scp>LAHRS</scp>) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Journal of Arrhythmia, 2022, 38, 491-553.	0.5	24
7	Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 1391-1398.	1.1	145
8	ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 1381-1390.	1.1	356
9	Novel cases of pediatric sudden cardiac death secondary to TRDN mutations presenting as long QT syndrome at rest and catecholaminergic polymorphic ventricular tachycardia during exercise: The TRDN arrhythmia syndrome. American Journal of Medical Genetics, Part A, 2021, 185, 3433-3445.	0.7	10
10	Human RyR2 (Ryanodine Receptor 2) Loss-of-Function Mutations. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010013.	2.1	18
11	Distinct Features of Probands With Early Repolarization and Brugada Syndromes Carrying SCN5A Pathogenic Variants. Journal of the American College of Cardiology, 2021, 78, 1603-1617.	1.2	22
12	Response to McGurk etÂal. Genetics in Medicine, 2021, , .	1.1	0
13	Endocrinopathies mimicking gene negative long QT syndrome. Cardiology in the Young, 2021, , 1-3.	0.4	0
14	Expanding the Clinical Phenotype of Emerinopathies. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009338.	2.1	2
15	Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada. Trials, 2020, 21, 647.	0.7	7
16	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms ofCASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2020, 142, 932-947.	1.6	44
17	COVID-19, Clinical Trials, and QT-Prolonging Prophylactic Therapy inÂHealthy Subjects. Journal of the American College of Cardiology, 2020, 75, 3184-3186.	1.2	9
18	Genetic Testing for Diagnosis of Hypertrophic Cardiomyopathy Mimics. Circulation Genomic and Precision Medicine, 2020, 13, e002748.	1.6	29

#	Article	IF	Citations
19	An International Multicenter Evaluation of Type 5 Long QT Syndrome. Circulation, 2020, 141, 429-439.	1.6	39
20	An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation, 2020, 141, 418-428.	1.6	238
21	Identification, clinical manifestation and structural mechanisms of mutations in AMPK associated cardiac glycogen storage disease. EBioMedicine, 2020, 54, 102723.	2.7	19
22	A Molecular Genetic Perspective on Atrial Fibrillation. , 2020, , 287-305.		0
23	TheÂPRKAG2 Cardiac Syndrome. , 2020, , 125-133.		0
24	Idiopathic Ventricular Fibrillation. , 2020, , 79-82.		0
25	Response by Wilde and Gollob to Letter Regarding Article, â€œReappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndromeâ€• Circulation, 2019, 139, 1760-1761.	1.6	5
26	Phospholamban cardiomyopathy: aÂCanadian perspective on aÂunique population. Netherlands Heart Journal, 2019, 27, 208-213.	0.3	15
27	Gene discovery: From biological plausibility to genetic evidence supporting disease causation. Heart Rhythm, 2019, 16, 1707-1709.	0.3	2
28	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. Journal of Clinical Investigation, 2019, 129, 3171-3184.	3.9	42
29	Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease. PLoS ONE, 2018, 13, e0197273.	1.1	3
30	Reappraisal of Reported Genes for Sudden Arrhythmic Death. Circulation, 2018, 138, 1195-1205.	1.6	271
31	Four TRPM4 Cation Channel Mutations Found in Cardiac Conduction Diseases Lead to Altered Protein Stability. Frontiers in Physiology, 2018, 9, 177.	1.3	40
32	Brugada syndrome: Let's talk about sex. Heart Rhythm, 2018, 15, 1466-1467.	0.3	4
33	T-Wave Morphology Analysis in CongenitalÂLong QT Syndrome Discriminates Patients From HealthyÂIndividuals. JACC: Clinical Electrophysiology, 2017, 3, 374-381.	1.3	29
34	Editorial commentary: Genetic testing in the absence of phenotype: When genetic testing may cause harm. Trends in Cardiovascular Medicine, 2017, 27, 214-215.	2.3	0
35	Bundle Branch Re-Entrant VentricularÂTachycardia. JACC: Clinical Electrophysiology, 2017, 3, 276-288.	1.3	27
36	The Phenotypic Spectrum of a MutationÂHotspot Responsible for theÂShort QT Syndrome. JACC: Clinical Electrophysiology, 2017, 3, 727-743.	1.3	58

#	Article	IF	Citations
37	Evaluation of Prolonged QT Interval: Structural Heart Disease Mimicking Long QT Syndrome. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 417-424.	0.5	7
38	Prevalence and Clinical Implication of Double Mutations in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	40
39	Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients. Journal of the American Heart Association, 2017, 6, .	1.6	38
40	Loss-of-Function KCNE2 Variants. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	31
41	Response to Letter Regarding Article, â€œOutcome of Apparently Unexplained Cardiac Arrest: Results From Investigation and Follow-Up of the Prospective Cardiac Arrest Survivors With Preserved Ejection Fraction Registryâ€. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e004012.	2.1	5
42	Usefulness of 14-Day Holter for Detection of Nonsustained Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 118, 1258-1263.	0.7	21
43	A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation. Nature Communications, 2016, 7, 11303.	5.8	106
44	Toward Translation of GenomicÂDiscoveryÂto Clinical Efficacy in Atrial Fibrillation â^—. Journal of the American College of Cardiology, 2016, 68, 1895-1897.	1.2	0
45	Rapid Deviceâ€Detected Nonsustained Ventricular Tachycardia in the Risk Stratification of Hypertrophic Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 642-651.	0.5	7
46	Primary prevention of idiopathic ventricular fibrillation: Not for the faint of heart. Heart Rhythm, 2016, 13, 913-914.	0.3	2
47	Outcome of Apparently Unexplained Cardiac Arrest. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003619.	2.1	56
48	Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. Journal of the American College of Cardiology, 2016, 67, 1300-1308.	1.2	154
49	Patient Outcomes From a Specialized Inherited Arrhythmia Clinic. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003440.	2.1	21
50	A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics Journal, 2016, 16, 71-78.	0.9	35
51	A Molecular Genetic Perspective on Atrial Fibrillation. , 2016, , 227-245.		0
52	Genetics of inherited primary arrhythmia disorders. The Application of Clinical Genetics, 2015, 8, 215.	1.4	21
53	Targeted Deep Sequencing Reveals No Definitive Evidence for Somatic Mosaicism in Atrial Fibrillation. Circulation: Cardiovascular Genetics, 2015, 8, 50-57.	5.1	15
54	Whole exome sequencing identifies the TNNI3K gene as a cause of familial conduction system disease and congenital junctional ectopic tachycardia. International Journal of Cardiology, 2015, 185, 114-116.	0.8	29

#	Article	IF	Citations
55	Epsilon Wave Uncovered by Exercise Test in a Patient With Desmoplakin-Positive Arrhythmogenic Right Ventricular Cardiomyopathy. Canadian Journal of Cardiology, 2015, 31, 819.e1-819.e2.	0.8	3
56	A practical guide to early repolarization. Current Opinion in Cardiology, 2015, 30, 8-16.	0.8	11
57	Go protein subunit GoÎ± and the secretory process of the natriuretic peptide hormones ANF and BNP. Journal of Molecular Endocrinology, 2015, 54, 277-288.	1.1	1
58	Reply: Noninvasive Measurement of Mouse Myocardial Glucose Uptake with ¹⁸F-FDG. Journal of Nuclear Medicine, 2014, 55, 866.2-867.	2.8	0
59	Atrioventricular Block as the Initial Manifestation of Cardiac Sarcoidosis in Middleâ€Aged Adults. Journal of Cardiovascular Electrophysiology, 2014, 25, 875-881.	0.8	150
60	A KCNQ1 mutation contributes to the concealed type 1 long QT phenotype by limiting the Kv7.1 channel conformational changes associated with protein kinase A phosphorylation. Heart Rhythm, 2014, 11, 459-468.	0.3	22
61	Procainamide infusion in the evaluation of unexplained cardiac arrest: From the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER). Heart Rhythm, 2014, 11, 1047-1054.	0.3	46
62	Evolution of a genetic diagnosis. Clinical Genetics, 2014, 86, 580-584.	1.0	3
63	Atrial arrhythmias in the young: early onset atrial arrhythmias preceding a diagnosis of a primary muscular dystrophy. Europace, 2014, 16, 1814-1820.	0.7	19
64	Integrating Genetic, Transcriptional, and Functional Analyses to Identify 5 Novel Genes for Atrial Fibrillation. Circulation, 2014, 130, 1225-1235.	1.6	183
65	Evaluation of Genes Encoding for the Transient Outward Current (Ito) Identifies the KCND2 Gene as a Cause of J-Wave Syndrome Associated With Sudden Cardiac Death. Circulation: Cardiovascular Genetics, 2014, 7, 782-789.	5.1	53
66	Evolution of clinical diagnosis in patients presenting with unexplained cardiac arrest or syncope due to polymorphic ventricular tachycardia. Heart Rhythm, 2014, 11, 274-281.	0.3	32
67	Myocardial infarction in a teenager. European Heart Journal, 2014, 35, 1558-1558.	1.0	9
68	First Report of a Large Duplication of the KCNQ1 Gene in a Patient With Long QT Syndrome. Canadian Journal of Cardiology, 2014, 30, 1249.e5-1249.e7.	0.8	0
69	A Contemporary Review on the Genetic Basis of Atrial Fibrillation. Methodist DeBakey Cardiovascular Journal, 2014, 10, 18-24.	0.5	18
70	Understanding the Genetic Basis of Atrial Fibrillation: Towards a Pharmacogenetic Approach for Arrhythmia Treatment. , 2014, , 65-75.		0
71	Chronic AMPK activity dysregulation produces myocardial insulin resistance in the human Arg302Gln-PRKAG2 glycogen storage disease mouse model. EJNMMI Research, 2013, 3, 48.	1.1	11
72	Early Repolarization: A Rare Primary Arrhythmic Syndrome and Common Modifier of Arrhythmic Risk. Journal of Cardiovascular Electrophysiology, 2013, 24, 837-843.	0.8	3

#	Article	IF	Citations
73	Long-Term Follow-Up of a Pediatric Cohort With Short QT Syndrome. Journal of the American College of Cardiology, 2013, 61, 1183-1191.	1.2	86
74	Atrial fibrillation as an autoimmune disease?. Heart Rhythm, 2013, 10, 442-443.	0.3	7
75	Exercise Testing in Asymptomatic Gene Carriers Exposes a Latent Electrical Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy. Journal of the American College of Cardiology, 2013, 62, 1772-1779.	1.2	64
76	Detection of genomic deletions of <scp>PKP2</scp> in arrhythmogenic right ventricular cardiomyopathy. Clinical Genetics, 2013, 83, 452-456.	1.0	37
77	Genetics of Cardiac Electrical Disease. Canadian Journal of Cardiology, 2013, 29, 89-99.	0.8	22
78	Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with ¹⁸F-FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model. Journal of Nuclear Medicine, 2013, 54, 1637-1644.	2.8	35
79	A KCNQ1 Mutation Causes a High Penetrance for Familial Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2013, 24, 562-569.	0.8	49
80	Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet, The, 2012, 379, 1705-1711.	6.3	341
81	The role of atrial natriuretic peptide in modulating cardiac electrophysiology. Heart Rhythm, 2012, 9, 610-615.	0.3	35
82	The Genetics of Cardiac Disease Associated with Sudden Cardiac Death. Journal of Molecular Diagnostics, 2012, 14, 424-436.	1.2	4
83	Distinguishing Pathogenic Mutations From Innocuous Rare Variants in Gene Discovery for Brugada Syndrome. Canadian Journal of Cardiology, 2012, 28, 160-161.	0.8	2
84	Epinephrine Infusion in the Evaluation of Unexplained Cardiac Arrest and Familial Sudden Death. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 933-940.	2.1	49
85	Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nature Genetics, 2012, 44, 670-675.	9.4	533
86	Voltage-Gated Sodium Channels: Biophysics, Pharmacology, and Related Channelopathies. Frontiers in Pharmacology, 2012, 3, 124.	1.6	95
87	Sentinel Symptoms in Patients with Unexplained Cardiac Arrest: From the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER). Journal of Cardiovascular Electrophysiology, 2012, 23, 60-66.	0.8	30
88	Reduced septal glucose metabolism predicts response to cardiac resynchronization therapy. Journal of Nuclear Cardiology, 2012, 19, 73-83.	1.4	16
89	The evolution of gene discovery and the revelation of truth. Heart Rhythm, 2011, 8, 410-411.	0.3	1
90	The Short QT Syndrome. Journal of the American College of Cardiology, 2011, 57, 802-812.	1.2	272

#	Article	IF	Citations
91	Prevalence and Characteristics of Early Repolarization in the CASPER Registry. Journal of the American College of Cardiology, 2011, 58, 722-728.	1.2	132
92	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Heart Rhythm, 2011, 8, 1308-1339.	0.3	995
93	Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2011, 8, 864-871.	0.3	171
94	Recommendations for the Use of Genetic Testing in the Clinical Evaluation of Inherited Cardiac Arrhythmias Associated with Sudden Cardiac Death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Paper. Canadian Journal of Cardiology, 2011, 27, 232-245.	0.8	139
95	A Novel Mutation in the RYR2 Gene Leading to Catecholaminergic Polymorphic Ventricular Tachycardia and Paroxysmal Atrial Fibrillation: Dose-Dependent Arrhythmia-Event Suppression by Î²-Blocker Therapy. Canadian Journal of Cardiology, 2011, 27, 870.e7-870.e10.	0.8	36
96	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace, 2011, 13, 1077-1109.	0.7	699
97	Psychological Adjustment in ICD Patients Living With Advisory Fidelis Leads. Journal of Cardiovascular Electrophysiology, 2011, 22, 57-63.	0.8	36
98	Derivation and Validation of a Simple Exercise-Based Algorithm for Prediction of Genetic Testing in Relatives of LQTS Probands. Circulation, 2011, 124, 2187-2194.	1.6	182
99	A Molecular Genetic Perspective on Atrial Fibrillation. , 2011, , 207-225.		0
100	Predictors of Fracture Risk of a Small Caliber Implantable Cardioverter Defibrillator Lead. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 437-443.	0.5	31
101	The genetic and clinical features of cardiac channelopathies. Future Cardiology, 2010, 6, 491-506.	0.5	15
102	Paradigm of Genetic Mosaicism and Lone Atrial Fibrillation. Circulation, 2010, 122, 236-244.	1.6	157
103	Evaluation of non-synonymous NPPA single nucleotide polymorphisms in atrial fibrillation. Europace, 2010, 12, 1078-1083.	0.7	24
104	Ventricular tachycardia following tube thoracotomy. Europace, 2010, 12, 1504-1506.	0.7	5
105	Characterization of a novel mutation in the cardiac ryanodine receptor that results in catecholaminergic polymorphic ventricular tachycardia. Channels, 2010, 4, 302-310.	1.5	28
106	Impact of Genetic Discoveries on the Classification of Lone Atrial Fibrillation. Journal of the American College of Cardiology, 2010, 55, 705-712.	1.2	89
107	Inherited cardiomyopathies mimicking arrhythmogenic right ventricular cardiomyopathy. Cardiovascular Pathology, 2010, 19, 316-320.	0.7	22
108	In-hospital mortality in 13,263 survivors of out-of-hospital cardiac arrest in Canada. American Heart Journal, 2010, 159, 577-583.e1.	1.2	14

#	Article	IF	Citations
109	Torsades de pointes during complete atrioventricular block: Genetic factors and electrocardiogram correlates. Canadian Journal of Cardiology, 2010, 26, 208-212.	0.8	28
110	Systematic Assessment of Patients With Unexplained Cardiac Arrest. Circulation, 2009, 120, 278-285.	1.6	280
111	In Vivo Assessment of Myocardial Glucose Uptake by Positron Emission Tomography in Adults With the PRKAG2 Cardiac Syndrome. Circulation: Cardiovascular Imaging, 2009, 2, 485-491.	1.3	15
112	Distinct Early Signaling Events Resulting From the Expression of the PRKAG2 R302Q Mutant of AMPK Contribute to Increased Myocardial Glycogen. Circulation: Cardiovascular Genetics, 2009, 2, 457-466.	5.1	31
113	Tenâ€Year Followâ€Up of Cardiac Sympathectomy in a Young Woman with Catecholaminergic Polymorphic Ventricular Tachycardia and an Implantable Cardioverter Defibrillator. Journal of Cardiovascular Electrophysiology, 2009, 20, 1167-1169.	0.8	15
114	Gain-of-function mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firing. Biochemical and Biophysical Research Communications, 2009, 380, 132-137.	1.0	105
115	Rapid genetic testing facilitating the diagnosis of short QT syndrome. Canadian Journal of Cardiology, 2009, 25, e133-e135.	0.8	25
116	Frequency and predictors of tachycardia-induced cardiomyopathy in patients with persistent atrial flutter. Canadian Journal of Cardiology, 2009, 25, 469-472.	0.8	57
117	Discrepant DNA analysis in three patients with inherited arrhythmia: Molecular genetic test results deserve a second glance. American Journal of Medical Genetics, Part A, 2008, 146A, 1466-1469.	0.7	2
118	Remote Magnetic Navigationâ€Assisted Catheter Ablation Enhances Catheter Stability and Ablation Success with Lower Catheter Temperatures. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 893-898.	0.5	54
119	Sudden Death in a Young Man with Catecholaminergic Polymorphic Ventricular Tachycardia and Paroxysmal Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2008, 19, 1319-1321.	0.8	91
120	Accelerating risk of Fidelis lead fracture. Heart Rhythm, 2008, 5, 1375-1379.	0.3	72
121	Begetting atrial fibrillation: Connexins and arrhythmogenesis. Heart Rhythm, 2008, 5, 888-891.	0.3	7
122	Inappropriate implantable cardioverter defibrillator shocks in fractured Sprint Fidelis leads associated with 'appropriate' interrogation. Europace, 2008, 10, 726-728.	0.7	6
123	No long-term psychological morbidity living with an implantable cardioverter defibrillator under advisory: the Medtronic Marquis experience. Europace, 2008, 11, 26-30.	0.7	24
124	Modulating Phenotypic Expression of the PRKAG2 Cardiac Syndrome. Circulation, 2008, 117, 134-135.	1.6	7
125	Use of implantable cardioverter defibrillators in Canadian and US survivors of out-of-hospital cardiac arrest. Cmaj, 2007, 177, 41-46.	0.9	41
126	Molecular autopsy in the sudden cardiac death of a young woman: A first Canadian report. Canadian Journal of Cardiology, 2007, 23, 904-906.	0.8	3

#	Article	IF	Citations
127	Electrical heart disease: Genetic and molecular basis of cardiac arrhythmias in normal structural hearts. Canadian Journal of Cardiology, 2007, 23, 16A-22A.	0.8	22
128	Normal Atrial Activation and Voltage During Sinus Rhythm in the Human Heart: An Endocardial and Epicardial Mapping Study in Patients with a History of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2007, 18, 402-408.	0.8	94
129	Transient left ventricular apical ballooning following a prolonged ablation. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 47-49.	0.6	3
130	Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm, 2006, 3, 1486-1489.	0.3	107
131	Feasibility study of endocardial mapping of ganglionated plexuses during catheter ablation of atrial fibrillation. Heart Rhythm, 2006, 3, 387-396.	0.3	196
132	Genetic determinants of atrial fibrillation: SNPs are riding the wave(lets). Heart Rhythm, 2006, 3, 813-814.	0.3	3
133	Clinical trials, the renin angiotensin system and atrial fibrillation. Current Opinion in Cardiology, 2006, 21, 368-375.	0.8	17
134	Cardiac connexins as candidate genes for idiopathic atrial fibrillation. Current Opinion in Cardiology, 2006, 21, 155-158.	0.8	26
135	Genetic profiling as a marker for risk of sudden cardiac death. Current Opinion in Cardiology, 2006, 21, 42-46.	0.8	9
136	Appropriate Result from an Inappropriate ICD Shock. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 1183-1184.	0.5	3
137	To the Editor:. Journal of Cardiovascular Electrophysiology, 2006, 17, E9-E9.	0.8	0
138	Successful ablation of a concealed parahisian accessory pathway using a remote magnetic navigation system following failure by conventional methods. Journal of Interventional Cardiac Electrophysiology, 2006, 16, 149-151.	0.6	11
139	Frequency of Peripartum Cardiomyopathy. American Journal of Cardiology, 2006, 97, 1765-1768.	0.7	231
140	Reasons for Escalating Pacemaker Implants. American Journal of Cardiology, 2006, 98, 93-97.	0.7	82
141	Molecular Cardiology and Genetics in the 21st Centuryâ€"A Primer. Current Problems in Cardiology, 2006, 31, 637-701.	1.1	7
142	Influence of gender on ICD implantation for primary and secondary prevention of sudden cardiac death. Europace, 2006, 8, 1054-1056.	0.7	19
143	Somatic Mutations in the Connexin 40 Gene (GJA5) in Atrial Fibrillation. New England Journal of Medicine, 2006, 354, 2677-2688.	13.9	510
144	An Unusual Accessory Pathway: Anteroseptal to Ventricular Outflow Region Connection. Journal of Cardiovascular Electrophysiology, 2005, 16, 546-551.	0.8	10

#	Article	IF	Citations
145	Transgenic Mouse Model of Ventricular Preexcitation and Atrioventricular Reentrant Tachycardia Induced by an AMP-Activated Protein Kinase Loss-of-Function Mutation Responsible for Wolff-Parkinson-White Syndrome. Circulation, 2005, 111, 21-29.	1.6	139
146	Diagnosis of Unexplained Cardiac Arrest. Circulation, 2005, 112, 2228-2234.	1.6	94
147	Stable Angina. , 2005, , 451-470.		0
148	Isorhythmic interaction between a dual-chamber pacemaker and an intrinsic rhythm: Pacemaker malfunctioning or not?. Heart Rhythm, 2004, 1, 752-755.	0.3	2
149	Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome. Biochemical Society Transactions, 2003, 31, 228-231.	1.6	58
150	AMP-activated protein kinase and familial Wolffâ€“Parkinsonâ€“White syndrome: new perspectives on heart development and arrhythmogenesis. European Heart Journal, 2002, 23, 679-681.	1.0	13
151	PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Current Opinion in Cardiology, 2002, 17, 229-234.	0.8	87
152	Current Status of the Implantable Cardioverter-Defibrillator. Chest, 2001, 119, 1210-1221.	0.4	31
153	Novel PRKAG2 Mutation Responsible for the Genetic Syndrome of Ventricular Preexcitation and Conduction System Disease With Childhood Onset and Absence of Cardiac Hypertrophy. Circulation, 2001, 104, 3030-3033.	1.6	254
154	Identification of a Gene Responsible for Familial Wolffâ€“Parkinsonâ€“White Syndrome. New England Journal of Medicine, 2001, 344, 1823-1831.	13.9	614
155	Accessory Atrioventricular Node with Properties of a Typical of a Typical Accessory Pathway:.. Journal of Cardiovascular Electrophysiology, 2000, 11, 922-926.	0.8	10
156	Genomics Perspective for Drug Discovery. , 0, , 339-358.		0